Fig. 2. repNP vaccination is efficacious in the absence of Fcγ Receptors, Complement, and NK cells.

WT C57BL6/J or B6NTac mice, FcγR^−/−, C3^−/− and WT mice depleted of NK cells were (a, b) vaccinated with 1ug of Sham or repNP RNA on day −28 relative to lethal CCHFV challenge. b WT mice were depleted of NK cells on Day −2, 1, 4, 7, and 10 relative to CCHFV challenge by IP treatment with NK1.1 antibody. On D0, groups of mice were evaluated for immunological response to vaccine or treated with MAR1-5A3 antibody and infected with a lethal dose of 100 TCID₅₀ CCHFV strain UG3010. Mice (N = 8) were (c) weighed daily and monitored for (d) survival until day 14 post-infection (p.i.). On D5 p.i., groups of mice (N = 6) were euthanized and evaluated for (e) viral genome copies via qRT-PCR and (f) infectious virus via TCID₅₀ in the blood, liver, and spleen. WT repNP mice are pooled C57BL/6 and B6NTac mice vaccinated with repNP RNA. Sham mice are pooled C57BL/6, B6NTac, FcγR^−/−, and C3^−/− mice vaccinated with Sham RNA. Dashed lines indicate limit of detection. Significance was calculated using one-way ANOVA; ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data shown as mean plus standard deviation.